University of South Florida

University of California

Industry-University Cooperation Foundation Hanyang University

Yu Chen

Adam Renslo

Priyadarshini Jaishankar

Xiujun Zhang

Orville Antonio Pemberton

James William Leahy

Xingmin Sun

Erica M W Lauterwasser

Michael Sacco

Elena Bray

Derek Nichols

Min Young Kim

Vladimir N Uversky

Stephen Bryant Liggett

Chul Geun Kim

Kyle Defrees

Dae Hyun Ha

Young Su Lim

Arjan Van Der Vaart

Young Yiul Lee

David E Kang

Eric Lewandowski

Buom Yong Ryu

Jung A Woo

Insung Na

Nicholas Joseph Torelli

Disclosed herein are compounds that can prevent and treatby inhibiting sporulation. Also disclosed herein are compositions and formulations comprising the compound disclosed herein. Methods of preventing and treatingcomprising administering the compounds described herein are also disclosed.

Small molecule inhibitors targetingsporulation

As disclosed herein, β-arrestin1 and β-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both β-arrestin1 and β-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when β-arrestin2 is overexpressed, tau levels become elevated. The data indicate that β-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of β-arrestin2. Therefore, disclosed herein are β-arrestin oligomerization inhibitors that can be used to prevent β-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor disclosed herein.

Inhibition of beta-arrestin oligomerization in tauopathy

Provided herein are heterocyclic compounds and pharmaceutical formulations that can be used to treat bacterial infections. Also provided herein are methods of making and using the heterocyclic compounds and pharmaceutical formulations.

Beta-lactamase inhibitors, formulations, and uses thereof

The present disclosure provides compositions including a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

Compositions, methods of use, and methods of treatment

The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66&#x3b1; (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.

Composition comprising compound inhibiting interactions of MBD2 and P66&#x3b1; for anti-metastasis and prevention and treatment of cancer disease

Embodiments of the present disclosure, in one aspect, relate to a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

Growing community of inventors

Tampa, FL, United States of America

Yu Chen